Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 EUR | +1.25% |
|
-3.61% | -4.19% |
06-06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
06-05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
Sales 2024 * | 750K 702K 59.38M | Sales 2025 * | 750K 702K 59.38M | Capitalization | 138M 129M 10.89B |
---|---|---|---|---|---|
Net income 2024 * | -143M -134M -11.32B | Net income 2025 * | -146M -137M -11.56B | EV / Sales 2024 * | 183 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 183 x |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-1.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.84% |
Latest transcript on I-Mab
1 week | -2.41% | ||
Current month | +3.85% | ||
3 months | -6.36% | ||
6 months | +13.29% | ||
Current year | -2.99% |
![Extreme 1.59](/images/extremecours_fleche.png)
![Extreme 1.46](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Rajkumar Kannan
CEO | Chief Executive Officer | 61 | 21/06/23 |
Jerry Wang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yi Fei Zhu
PRN | Corporate Officer/Principal | 55 | 09/08/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chia Hung Yang
BRD | Director/Board Member | 61 | 31/12/19 |
Pamela Klein
CHM | Chairman | 63 | 31/12/19 |
Shuai Chen
BRD | Director/Board Member | 50 | 31/03/23 |
Date | Price | Change |
---|---|---|
26/06/24 | 1.62 | +1.25% |
25/06/24 | 1.6 | +0.63% |
24/06/24 | 1.59 | 0.00% |
21/06/24 | 1.59 | 0.00% |
20/06/24 | 1.59 | -4.22% |
Real-time BOERSE MUENCHEN, June 26, 2024 at 08:44 pm
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |
- Stock Market
- Equities
- IMAB Stock
- 0VY Stock